Skip to main content

Advertisement

ADVERTISEMENT

ADHD

Results of a phase IV, open-label safety study evaluating viloxazine ER (Qelbree®) administered with psychostimulants in pediatric (6-17 years) ADHD; morning vs. evening administration of...
10/26/2023
Final results of a long-term, open-label extension of a pivotal phase 3 study leading to FDA-approval of viloxazine extended-release capsules (Qelbree®) in adults.
10/26/2023
DR/ER-MPH is an evening-dosed delayed-release and extended-release methylphenidate that is released in the colon and provides a dose-dependent duration of effect for individuals aged ≥6y ...
10/26/2023
Centanafadine (CTN) is a norepinephrine/dopamine/serotonin reuptake inhibitor being investigated for the treatment of attention-deficit/hyperactivity disorder (ADHD). Secondary efficacy o...
10/26/2023
Centanafadine (CTN) is a novel norepinephrine/dopamine/serotonin reuptake inhibitor in development for attention-deficit/hyperactivity disorder (ADHD). Long-term (52 weeks) safety and exp...
10/26/2023
Cingulate has conducted a Phase 3 randomized, placebo controlled efficacy and safety study along with onset and duration in 21 adults with ADHD using CTx-1301 in a laboratory classroom se...
10/26/2023
In a pivotal study, d-ATS applied to the hip met primary and secondary efficacy endpoints for ADHD in children and adolescents. In this open-label crossover study, healthy adults were ran...
10/26/2023
Centanafadine is a norepinephrine/dopamine/serotonin reuptake inhibitor in development for treatment of attention-deficit/hyperactivity disorder (ADHD). The effect of centanafadine on car...
10/26/2023
Dr Greg Mattingly
Videos
09/05/2023

With Greg Mattingly, MD

With Greg Mattingly, MD
Dr Mattingly explains the stimluant shortage and what clinicians can do to help their patients.
Dr Mattingly explains the stimluant shortage and what clinicians can do to help their patients.
Dr Mattingly explains the...
09/05/2023
Psych Congress Network
Abstract: Viloxazine ER (viloxazine extended-release capsules, Qelbree®) is a novel, nonstimulant, FDA-approved treatment for adults and children (≥6 yrs) with ADHD. Viloxazine ER inhibit...
01/19/2023
Abstract: Aim: To evaluate changes in attention-deficit hyperactivity disorder (ADHD) severity in children (aged 6-12 years) posttreatment with serdexmethylphenidate/dexmethylphenidate (S...
01/19/2023
Abstract: Aim: To quantify the value of Azstarys (serdexmethylphenidate/dexmethylphenidate) for patients with attention-deficit hyperactivity disorder (ADHD) with real-world data from the...
01/19/2023
Abstract: Viloxazine ER is a novel, nonstimulant, FDA-approved treatment for ADHD in children and adults (≥ 6 years). Viloxazine ER effects on executive function (EF) deficits were evalua...
01/19/2023
Abstract: Viloxazine ER (Qelbree®) is a novel, nonstimulant, FDA-approved treatment for ADHD in pediatric patients (≥6 years) and adults. The efficacy of viloxazine ER was evaluated in 4 ...
01/19/2023
Abstract: Purpose: Immediate-release methylphenidate (IR MPH) is sometimes dosed in the afternoon to extend the duration of effect of a morning-dosed extended-release (ER) MPH for attenti...
01/19/2023
Abstract: Background: In a pivotal study, the dextroamphetamine transdermal system (d-ATS) met primary and secondary efficacy endpoints for ADHD in children and adolescents. This post-hoc...
01/19/2023
Abstract: Aim: To determine sleep behavior during serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) treatment in children with attention-deficit hyperactivity disorder (ADHD). Method...
01/19/2023
Abstract: Purpose: Emotional lability (EL) is commonly seen in individuals with attention-deficit/hyperactivity disorder (ADHD). A post hoc analysis found that DR/ER-MPH (formerly HLD200)...
01/19/2023

Advertisement